NASDAQ:CEMI - Chembio Diagnostics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.04 -0.22 (-3.51 %)
(As of 11/21/2018 08:00 AM ET)
Previous Close$6.26
Today's Range$5.93 - $6.40
52-Week Range$5.72 - $11.55
Volume64,400 shs
Average Volume218,305 shs
Market Capitalization$107.59 million
P/E RatioN/A
Dividend YieldN/A
Beta1.46
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or monitor diseases. It offers tests for HIV and Syphilis, and Zika virus. The company also develops tests for malaria, Dengue virus, chikungunya virus, Ebola, Lassa, Marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC for the development of a POC diagnostic test for traumatic brain injury; international diagnostics company to develop a POC diagnostic test for a specific type of cancer; and AstraZeneca for the development of a POC assay for a novel biomarker, as well as with LumiraDx to develop POC diagnostic tests. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.

Receive CEMI News and Ratings via Email

Sign-up to receive the latest news and ratings for CEMI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CEMI
Previous Symbol
CUSIPN/A
Phone631-924-1135

Debt

Debt-to-Equity Ratio0.01
Current Ratio2.86
Quick Ratio2.09

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$24.01 million
Price / Sales4.32
Cash FlowN/A
Price / CashN/A
Book Value$1.14 per share
Price / Book5.30

Profitability

EPS (Most Recent Fiscal Year)($0.52)
Net Income$-6,370,000.00
Net Margins-21.04%
Return on Equity-34.10%
Return on Assets-26.07%

Miscellaneous

Employees165
Outstanding Shares17,190,000
Market Cap$107.59 million
OptionableNot Optionable

Chembio Diagnostics (NASDAQ:CEMI) Frequently Asked Questions

What is Chembio Diagnostics' stock symbol?

Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics Inc (NASDAQ:CEMI) announced its quarterly earnings data on Thursday, November, 8th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $0.10. The company had revenue of $9.38 million for the quarter. Chembio Diagnostics had a negative return on equity of 34.10% and a negative net margin of 21.04%. View Chembio Diagnostics' Earnings History.

When is Chembio Diagnostics' next earnings date?

Chembio Diagnostics is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Chembio Diagnostics.

What guidance has Chembio Diagnostics issued on next quarter's earnings?

Chembio Diagnostics updated its third quarter 2018 earnings guidance on Monday, October, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $9.2-9.4 million, compared to the consensus revenue estimate of $8.1 million.

What price target have analysts set for CEMI?

1 brokers have issued 1 year price targets for Chembio Diagnostics' stock. Their predictions range from $14.00 to $14.00. On average, they anticipate Chembio Diagnostics' stock price to reach $14.00 in the next year. This suggests a possible upside of 131.8% from the stock's current price. View Analyst Price Targets for Chembio Diagnostics.

What is the consensus analysts' recommendation for Chembio Diagnostics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chembio Diagnostics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chembio Diagnostics.

Has Chembio Diagnostics been receiving favorable news coverage?

Media coverage about CEMI stock has been trending somewhat negative on Wednesday, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Chembio Diagnostics earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days.

Who are some of Chembio Diagnostics' key competitors?

Who are Chembio Diagnostics' key executives?

Chembio Diagnostics' management team includes the folowing people:
  • Mr. John J. Sperzel III, Pres, CEO & Director (Age 54)
  • Mr. Neil A. Goldman, Exec. VP & CFO (Age 50)
  • Mr. Javan Esfandiari, Chief Science & Technology Officer and Exec. VP (Age 51)
  • Ms. Sharon Klugewicz, Sr. VP and Chief Quality & Regulatory Officer (Age 50)
  • Dr. Robert Passas Ph.D., Sr. VP & Chief Commercial Officer (Age 64)

Who are Chembio Diagnostics' major shareholders?

Chembio Diagnostics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include ARS Investment Partners LLC (5.11%), Royce & Associates LP (1.86%), Ingalls & Snyder LLC (2.15%), Wells Fargo & Company MN (1.00%) and Renaissance Technologies LLC (0.25%). Company insiders that own Chembio Diagnostics stock include John Gary Potthoff, Neil A Goldman, Norman H Pessin and Robert Passas. View Institutional Ownership Trends for Chembio Diagnostics.

Which major investors are buying Chembio Diagnostics stock?

CEMI stock was purchased by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, ARS Investment Partners LLC, Renaissance Technologies LLC, Royce & Associates LP and Wells Fargo & Company MN. Company insiders that have bought Chembio Diagnostics stock in the last two years include John Gary Potthoff, Neil A Goldman, Norman H Pessin and Robert Passas. View Insider Buying and Selling for Chembio Diagnostics.

How do I buy shares of Chembio Diagnostics?

Shares of CEMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chembio Diagnostics' stock price today?

One share of CEMI stock can currently be purchased for approximately $6.04.

How big of a company is Chembio Diagnostics?

Chembio Diagnostics has a market capitalization of $107.59 million and generates $24.01 million in revenue each year. The company earns $-6,370,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Chembio Diagnostics employs 165 workers across the globe.

What is Chembio Diagnostics' official website?

The official website for Chembio Diagnostics is http://www.chembio.com.

How can I contact Chembio Diagnostics?

Chembio Diagnostics' mailing address is 3661 HORSEBLOCK ROAD, MEDFORD NY, 11763. The company can be reached via phone at 631-924-1135 or via email at [email protected]


MarketBeat Community Rating for Chembio Diagnostics (NASDAQ CEMI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  108 (Vote Outperform)
Underperform Votes:  111 (Vote Underperform)
Total Votes:  219
MarketBeat's community ratings are surveys of what our community members think about Chembio Diagnostics and other stocks. Vote "Outperform" if you believe CEMI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CEMI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel